SG11201603306TA - Salmonella conjugate vaccines - Google Patents
Salmonella conjugate vaccinesInfo
- Publication number
- SG11201603306TA SG11201603306TA SG11201603306TA SG11201603306TA SG11201603306TA SG 11201603306T A SG11201603306T A SG 11201603306TA SG 11201603306T A SG11201603306T A SG 11201603306TA SG 11201603306T A SG11201603306T A SG 11201603306TA SG 11201603306T A SG11201603306T A SG 11201603306TA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugate vaccines
- salmonella
- salmonella conjugate
- vaccines
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20130192176 EP2870974A1 (en) | 2013-11-08 | 2013-11-08 | Salmonella conjugate vaccines |
PCT/IB2014/065869 WO2015068129A1 (en) | 2013-11-08 | 2014-11-07 | Salmonella conjugate vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201603306TA true SG11201603306TA (en) | 2016-05-30 |
Family
ID=49551548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603306TA SG11201603306TA (en) | 2013-11-08 | 2014-11-07 | Salmonella conjugate vaccines |
Country Status (15)
Country | Link |
---|---|
US (1) | US10098947B2 (en) |
EP (2) | EP2870974A1 (en) |
JP (1) | JP6289632B2 (en) |
KR (2) | KR102112663B1 (en) |
CN (1) | CN105828839B (en) |
AU (1) | AU2014347722B2 (en) |
BR (1) | BR112016010072B1 (en) |
CA (1) | CA2929114C (en) |
EA (1) | EA033491B1 (en) |
ES (1) | ES2828039T3 (en) |
IL (1) | IL245217B (en) |
MX (1) | MX358829B (en) |
SG (1) | SG11201603306TA (en) |
WO (1) | WO2015068129A1 (en) |
ZA (1) | ZA201602834B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2758090C2 (en) * | 2016-03-15 | 2021-10-26 | Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. | New conjugates of polysaccharide with protein and their preparation method |
WO2018096007A2 (en) * | 2016-11-25 | 2018-05-31 | Glaxosmithkline Biologicals S.A. | Immunogenic conjugates and use thereof |
MX2021005500A (en) * | 2018-11-10 | 2021-09-08 | Bharat Biotech Int Ltd | Multivalent glycoconjugates immunogenic compositions. |
EP4253554A3 (en) * | 2019-03-18 | 2024-01-17 | Janssen Pharmaceuticals, Inc. | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
CN110018253A (en) * | 2019-04-15 | 2019-07-16 | 艾美卫信生物药业(浙江)有限公司 | The high-efficient liquid phase determining method of Free protein content in a kind of biological products |
EP4061412A1 (en) | 2019-11-22 | 2022-09-28 | GlaxoSmithKline Biologicals S.A. | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
KR102493192B1 (en) * | 2021-07-20 | 2023-01-30 | 에스케이바이오사이언스(주) | Vaccine composition comprising conjugate of capsular polysaccharide derived from Salmonella typhi and protein |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
IT1214609B (en) * | 1985-05-17 | 1990-01-18 | Opocrin Spa | HEXOSAMINOGLICANS DEPOLYMERIZED SULPHATES FOR ANTI-THROMBOTIC, FIBRINOLITHIC, ANTI-INFLAMMATORY ACTIVITIES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US4874854A (en) * | 1985-10-08 | 1989-10-17 | Merck & Co., Inc. | Low viscosity heteropolysaccharides |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
DE68917126T2 (en) * | 1988-02-01 | 1995-02-02 | Praxis Biolog Inc | T-CELL EPITOPE AS A SUPPORT FOR A CONJUGATED VACCINE. |
US5204098A (en) * | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
DK0872478T3 (en) | 1991-03-01 | 2003-03-31 | Minnesota Mining & Mfg | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo [4,5-c] quinoline-4-amines |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
FR2682388B1 (en) | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | PROCESS FOR THE PREPARATION OF AN OLIGOSIDE BY DEPOLYMERIZATION OF A POLYOSIDE DERIVED FROM A PATHOGENIC AGENT, OLIGOSIDE THUS OBTAINED AND ITS USE IN PARTICULAR AS A VACCINE AGENT. |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5736146A (en) * | 1992-07-30 | 1998-04-07 | Yeda Research And Development Co. Ltd. | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
CN1087176C (en) | 1993-03-23 | 2002-07-10 | 史密斯克莱·比奇曼生物公司 | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
DK0708772T3 (en) | 1993-07-15 | 2000-09-18 | Minnesota Mining & Mfg | Imidazo [4,5-c] pyridin-4-amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
IL109790A0 (en) * | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5872246A (en) * | 1994-10-17 | 1999-02-16 | Aqualon Company | Ethyl guar |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
AU725279B2 (en) * | 1995-06-07 | 2000-10-12 | Alberta Research Council Inc. | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them |
WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
JPH1119664A (en) * | 1997-07-04 | 1999-01-26 | Kazuyoshi Matsunaga | Decomposition of hardly biologically decomposable organic matter and removing method of phosphorus by zirconium oxide/ferric salt/hydrogen peroxide/ ultraviolet rays system |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
EP2266604A3 (en) | 1998-10-16 | 2011-05-11 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
ES2228467T3 (en) | 1999-02-03 | 2005-04-16 | Biosante Pharmaceuticals, Inc. | THERAPEUTIC PARTICLES OF CALCIUM PHOSPHATE AND METHODS OF MANUFACTURE AND ITS USE. |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
RU2245149C2 (en) | 1999-09-25 | 2005-01-27 | Юниверсити Оф Айова Рисерч Фаундейшн | Immunostimulating nucleic acids |
WO2001095935A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US6756383B2 (en) | 2000-09-01 | 2004-06-29 | Chiron Corporation | Heterocyclic derivatives of quinolinone benimidazoles |
CZ304344B6 (en) | 2000-09-11 | 2014-03-19 | Novartis Vaccines & Diagnostics, Inc. | Quinolinone derivatives and their use as well as pharmaceutical compositions in which the derivatives are comprised |
UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
DE60234376D1 (en) | 2001-11-27 | 2009-12-24 | Anadys Pharmaceuticals Inc | 3-BETA-D-RIBOFURANOSYLTHIAZOLO (4,5-DELTA) PYRIDIMINE NUCLEOSIDE AND ITS USE |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
NZ535985A (en) | 2002-03-29 | 2007-04-27 | Chiron Corp | Substituted benzazoles and use thereof as RAF kinase inhibitors |
WO2003101949A2 (en) | 2002-05-29 | 2003-12-11 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
ATE477251T1 (en) | 2002-08-23 | 2010-08-15 | Novartis Vaccines & Diagnostic | PYRROLE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS |
BR0316271A (en) * | 2002-11-14 | 2005-10-11 | Inst Finlay Ct De Investigacio | Method for obtaining multivalent conjugate vaccine preparations, multivalent vaccine composition and use thereof |
CN1404873A (en) * | 2002-11-22 | 2003-03-26 | 北京绿竹生物技术有限责任公司 | Typhoid vaccine |
WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
EP1651262A2 (en) * | 2003-08-06 | 2006-05-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Process for preparing polysaccharide-protein conjugate vaccines |
PT2336147E (en) * | 2003-12-17 | 2014-07-16 | Janssen Alzheimer Immunotherap | A beta immunogenic peptide carrier conjugates and methods of producing same |
KR20090051129A (en) | 2004-04-05 | 2009-05-20 | 화이자 프로덕츠 인코포레이티드 | Microfluidized oil-in-water emulsions and vaccine compositions |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
GB0810894D0 (en) * | 2008-06-13 | 2008-07-23 | Novartis Vaccines & Diagnostic | Conjugated saccharide |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
GB201003924D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
-
2013
- 2013-11-08 EP EP20130192176 patent/EP2870974A1/en not_active Ceased
-
2014
- 2014-11-07 CA CA2929114A patent/CA2929114C/en active Active
- 2014-11-07 BR BR112016010072-7A patent/BR112016010072B1/en active IP Right Grant
- 2014-11-07 US US15/033,946 patent/US10098947B2/en active Active
- 2014-11-07 ES ES14799018T patent/ES2828039T3/en active Active
- 2014-11-07 EA EA201690857A patent/EA033491B1/en not_active IP Right Cessation
- 2014-11-07 WO PCT/IB2014/065869 patent/WO2015068129A1/en active Application Filing
- 2014-11-07 CN CN201480061264.6A patent/CN105828839B/en active Active
- 2014-11-07 SG SG11201603306TA patent/SG11201603306TA/en unknown
- 2014-11-07 AU AU2014347722A patent/AU2014347722B2/en active Active
- 2014-11-07 JP JP2016528102A patent/JP6289632B2/en active Active
- 2014-11-07 KR KR1020197003712A patent/KR102112663B1/en active IP Right Grant
- 2014-11-07 KR KR1020167014954A patent/KR20160079874A/en active IP Right Grant
- 2014-11-07 MX MX2016006001A patent/MX358829B/en active IP Right Grant
- 2014-11-07 EP EP14799018.8A patent/EP3065781B1/en active Active
-
2016
- 2016-04-20 IL IL245217A patent/IL245217B/en active IP Right Grant
- 2016-04-25 ZA ZA2016/02834A patent/ZA201602834B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10098947B2 (en) | 2018-10-16 |
MX358829B (en) | 2018-09-05 |
AU2014347722A1 (en) | 2016-06-02 |
KR20190015641A (en) | 2019-02-13 |
EA201690857A1 (en) | 2016-10-31 |
BR112016010072B1 (en) | 2021-06-08 |
KR102112663B1 (en) | 2020-05-19 |
CA2929114A1 (en) | 2015-05-14 |
CA2929114C (en) | 2023-08-22 |
ZA201602834B (en) | 2020-01-29 |
JP6289632B2 (en) | 2018-03-07 |
IL245217A0 (en) | 2016-06-30 |
IL245217B (en) | 2021-03-25 |
JP2016536317A (en) | 2016-11-24 |
AU2014347722B2 (en) | 2017-10-26 |
EA033491B1 (en) | 2019-10-31 |
EP3065781B1 (en) | 2020-08-05 |
EP2870974A1 (en) | 2015-05-13 |
EP3065781A1 (en) | 2016-09-14 |
ES2828039T3 (en) | 2021-05-25 |
WO2015068129A1 (en) | 2015-05-14 |
US20160263213A1 (en) | 2016-09-15 |
KR20160079874A (en) | 2016-07-06 |
BR112016010072A8 (en) | 2020-04-14 |
CN105828839A (en) | 2016-08-03 |
MX2016006001A (en) | 2016-07-22 |
CN105828839B (en) | 2020-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276210A (en) | Mers-cov vaccine | |
IL279395A (en) | Vaccine composition | |
HRP20181376T1 (en) | Improved poxviral vaccines | |
HK1211224A1 (en) | Multivalent glycoconjugate vaccines | |
SG11201507883SA (en) | Wt1-antigen peptide conjugate vaccine | |
GB201308131D0 (en) | Ophthalmoscope | |
ZA201602834B (en) | Salmonella conjugate vaccines | |
GB201301085D0 (en) | Glycoconjugate Vaccine | |
PL3048936T3 (en) | Device for preparing food | |
HK1217206A1 (en) | Vaccine | |
GB201309664D0 (en) | Fish vaccine | |
PL3086655T3 (en) | Aroma-retaining soluble coffee | |
HK1215561A1 (en) | Portion capsule | |
HK1216149A1 (en) | Campylobacter vaccine | |
AU353529S (en) | Toaster | |
GB2516476B (en) | Toaster | |
PL2911688T3 (en) | Cross-protecting salmonella vaccines | |
GB201320646D0 (en) | Vaccine | |
GB201315556D0 (en) | Vaccine | |
GB201320421D0 (en) | Conjugated vaccine | |
GB201310280D0 (en) | Odontalgic preparation | |
AU353447S (en) | Toaster | |
GB201315591D0 (en) | Toaster | |
GB201315372D0 (en) | Barbecue/cook-station | |
GB201322342D0 (en) | Procedure |